[EN] NEW AZABENZIMIDAZOLE DERIVATIVES<br/>[FR] NOUVEAUX DÉRIVÉS D'AZABENZIMIDAZOLE
申请人:BOEHRINGER INGELHEIM INT
公开号:WO2015007669A1
公开(公告)日:2015-01-22
The present invention relates to compounds of general formula (I), wherein the group R1, R2, X and Y are defined as in claim 1, which have valuable pharmacological properties, in particular bind to the AMP-activated protein kinase (AMPK) and modulate its activity. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular diabetes type 2.
The present invention relates to compounds of general formula I,
wherein the group R
1
, R
2
, X and Y are defined as in claim
1
, which have valuable pharmacological properties, in particular bind to the AMP-activated protein kinase (AMPK) and modulate its activity. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular diabetes type 2.
[EN] KINASE INHIBITORS AND USES THEREOF<br/>[FR] INHIBITEURS DE KINASE ET LEURS UTILISATIONS
申请人:DENALI THERAPEUTICS INC
公开号:WO2018213632A1
公开(公告)日:2018-11-22
The present disclosure relates generally to compounds and compositions, intermediates, processes for their preparation, and their use as kinase inhibitors.
Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors
申请人:Turner Sean Colm
公开号:US09266855B2
公开(公告)日:2016-02-23
The present invention relates to novel heterocyclic compounds which are useful for inhibiting glycogen synthase kinase 3 (GSK-3), methods of making the compounds, compositions containing the compounds, and methods of treatment using the compounds.